Supplementary - Combi-TED_-_Study_Protocol_v3.0_09.06.2022 (1).pdf (2.18 MB)

Combi-TED: a new trial testing Tedopi R with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line study protocol

dataset

posted on 2023-05-11, 16:40 authored by Lorenza Landi, Angelo Delmonte, Andrea Bonetti, Giulia Pasello, Giulio Metro, Francesca Mazzoni, Gloria Borra, Diana Giannarelli, Kalliopi Andrikou, Daniela Mangiola, Stefania Gori, Mario Rosario D’Andrea, Gabriele Minuti, Blerina Resuli, Anastasia Laudisi, Antonello Vidiri, Laura Conti, Federico Cappuzzo

Combi-TED: a new trial testing Tedopi R with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line study protocol

Funding

The study is funded by Fondazione Ricerca Traslazionale (FoRT). G Pasello is an Advisor/Consultant for AstraZeneca, Lilly, MSD, Roche, Takeda and Novartis. He received unconditioned research support from AstraZeneca and Roche. The other authors have no conflicts of interest to declare. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

History

Usage metrics

Categories

Cancer therapy (excl. chemotherapy and radiation therapy)

Keywords

chemo-immunotherapy docetaxel nivolumab non-small-cell lung cancer overall survival phase II trial Tedopi

Licence

CC BY-NC-ND 4.0

Exports